cervical cancer – Medxy AI

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial

By MedXY 09/14/2026

Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.

news OB/GYN & Women's Health Oncology

Minimally Invasive Radical Hysterectomy Without Uterine Manipulator vs Open Surgery for Early-Stage Cervical Cancer: Comparative Outcomes from a Large Propensity-Matched Cohort

By MedXY 09/11/2026

This retrospective study compares oncologic and perioperative outcomes of minimally invasive radical hysterectomy without uterine manipulator versus open radical hysterectomy in early-stage cervical cancer, showing comparable survival but improved perioperative recovery with MIS.

news OB/GYN & Women's Health Oncology

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data

By MedXY 08/22/2026

This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.

news OB/GYN & Women’s Health Oncology

Quality of Life and Morbidity Outcomes After Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-Stage Cervical Cancer: Insights from the SENTIX Study

By MedXY 08/17/2026

The SENTIX study demonstrates that sentinel lymph node biopsy preserves quality of life, reduces lymphoedema incidence, and lowers early postoperative complications compared to pelvic lymphadenectomy in early-stage cervical cancer patients.

news OB/GYN & Women’s Health Oncology

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy

By MedXY 08/14/2026

HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.

news OB/GYN & Women’s Health Oncology

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors

By MedXY 07/20/2026

Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased oncologic harm.

news OB/GYN & Women’s Health Pathology & Lab Medicine/Bệnh học

Enhancing Triage of Non-16/18 High-Risk HPV Cervical Lesions Using FAM19A4, SOX1, and PAX1 Methylation Testing

By MedXY 06/25/2026

FAM19A4, SOX1, and PAX1 methylation assays demonstrate high diagnostic accuracy for identifying CIN3+ among non-16/18 hrHPV-positive women, outperforming cytology and reducing unnecessary colposcopies.

news OB/GYN & Women’s Health Oncology

Pelvic Exenteration for Recurrent Cervical Cancer Can Deliver Long-Term Survival, but Survivorship Burden Remains Substantial

By MedXY 06/11/2026

A mixed-methods study suggests pelvic exenteration offers meaningful long-term survival in selected patients with recurrent cervical cancer, while qualitative data reveal persistent physical, social, and sexual burdens that standardized quality-of-life measures may underestimate.

news OB/GYN & Women’s Health Oncology

Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States

By MedXY 05/20/2026

Pembrolizumab plus chemoradiotherapy improved survival and quality-adjusted survival for FIGO 2014 stage III-IVA cervical cancer and was projected to be cost-effective in the U.S. at a $150,000/QALY threshold.

news OB/GYN & Women's Health Oncology

New Cervical Cancer Screening Guidelines: Patient-Collected HPV Tests Now Recommended

By Zhang Paul 04/30/2026

Introduction and Context Despite being highly preventable, cervical cancer remains a significant health threat. The…

news Oncology

ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications

By MedXY 04/26/2026

The American College of Obstetricians and Gynecologists (ACOG) has qualifiedly endorsed the 2026 WPSI cervical cancer screening guidelines. This article details the core recommendations, highlights key updates including self-collection options, and explores expert perspectives on implementation.

news OB/GYN & Women's Health Oncology

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

By MedXY 04/06/2026

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recurrence location relative to previous radiotherapy fields.

news Oncology

The Shift Toward De-escalation: Why Radical Trachelectomy Is Losing Ground in Early-Stage Cervical Cancer

By MedXY 03/15/2026

A multi-database analysis reveals a significant decline in trachelectomy utilization since 2016. With comparable 10-year survival rates between trachelectomy and conization, clinical practice is rapidly shifting toward less radical, fertility-sparing surgical interventions for low-risk cervical cancer.

news

Optimizing Cervical Cancer Screening for Women Living with HIV: New Data Supports Starting at Age 25

By MedXY 02/19/2026

A large-scale meta-analysis reveals age-specific risks for cervical precancer in women living with HIV, justifying the WHO recommendation to initiate screening at age 25 with 3–5 year intervals to mitigate high recurrence and progression rates.

news OB/GYN & Women's Health Oncology

Simple vs Radical Hysterectomy: Balancing Survival Outcomes and Quality of Life in Early Cervical Cancer

By MedXY 12/16/2025

Evidence suggests simple hysterectomy with pelvic lymphadenectomy may offer similar survival outcomes to radical hysterectomy in early-stage cervical cancer, with fewer adverse events and better short-term quality of life.

news OB/GYN & Women's Health Public Health

Long-Term Effectiveness of HPV Screen-and-Treat Strategy Versus Cytology in Cervical Cancer Screening: Insights from El Salvador’s CAPE Program

By MedXY 10/31/2025

A 5-year follow-up study in El Salvador demonstrates that primary HPV screen-and-treat significantly reduces CIN2+ detection and HPV positivity compared to cytology, supporting extended screening intervals in low-resource settings.

news OB/GYN & Women's Health Public Health

Review for Cervical Cancer Screening

By MedXY 10/31/2025

A comprehensive 2025 systematic review informing the Canadian Task Force finds cytology remains effective into the 60s, HPV-based strategies detect more precursors but increase colposcopy and false positives, and self-sampling improves uptake in underscreened people.

news Oncology

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY 10/25/2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

news Oncology

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY 10/25/2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

news OB/GYN & Women's Health Oncology Specialties

Impact of Treatment Recommendation and Receipt on Survival in Older Women with Early-Stage Cervical Cancer

By MedXY 09/24/2025

This study reveals that among women aged 65 and older with early-stage cervical cancer, those who receive recommended treatment—surgery and/or radiotherapy—exhibit significantly higher survival rates, emphasizing the need to overcome treatment barriers in this population.